+ Watch IPXL
on My Watchlist
Zacks #1 Rank and their Bull-of-the-Day pick for today.
major IHS pattern
01/21/2013 FDA decision on Rytary for treatment of idiopathic Parkinson's disease.
Great potential with its drug candidate IPX066.
I was already eyeing Impax for an outperform when the company dropped sharply intraday on word that the CFO was leaving the company. Now, no one likes change, but a 10% drop for a change in CFO seems excessive. Generic Adderall revenues are a little too lumpy for my taste but the company made a good move in acquiring Zomig. I think quality control warning letters from the FDA are being overblown and IPX066 stands a decent chance of first pass FDA approval in October. Today's drop was the first time the stock went below 20 since February, and barring a broad market meltdown I'd be surprised to see it cross that level again.
With better management and teeth clinching legal respondents, the CROX is monopolizing the fun relaxing, medical shoe market. Their emphasis on children is strong and retail outlets are growing. Just go to the mall and count how many people you see wearing Crox. They are also attacking the leather shoe side of things with a Sperry-like model now out.
I'm waiting for the MACD (12,26,9) to upcross the MACD signal line. The fundamentals look good, so I'm just trying to time my purchase.
The numbers are kinda insane.market cap $1.43 billionp/e 5PEG 0.72profit margin 28%operating margin 47%ROE 83%cash $358 millionno debtrevenue 2008: $210 millionrevenue 2009: $358 million (70% growth)revenue 2010: $580 million (through 3 quarters, should be over $700 million for the year, 100% growth).earnings 2008: $18 millionearnings 2009: $50 million (175% growth)earnings 2010: $180 million (through 3 quarters, should easily pass $200 million for year, or 300% growth)One of the reasons this stock is so cheap is because the generic market is hard to predict. Here are the revenues for the last four quarters: $176 million, $323 million, $153 million, $303 million. So the general direction is up but there's a huge fluctuation. The way the generic model works, the first to file has six months of exclusivity (i.e. has a duopoly with the original drug maker). But after that the drug prices usually fall through the floor. Add to this uncertainty all the litigation in the sector, and the race to file first, and you have a really unpredictable business model. On the plus side, they have a huge pipeline. They have filed for drug approval for 33 drugs with the FDA. At least eight of those have first-to-file or first-to-market potential. Some of those are likely to surprise to the upside. What is a small or unprofitable drug for a big pharma can be a nice money-maker for a generic company who sells the hell out of it at a cheaper price. And of course some of them will not surprise at all. For instance, they just got a tentative approval for Cymbalta, the anti-depression drug ($3 billion in annual sales). It goes off-patent in two years. So just write in an extra $600 million in sales for 2013. In the short term, we're all expecting bad news. There's been a huge demand for their ADD drug and Shire (the original drug maker) is supposed to supply them with unlimited quantities. Shire has been screwing them over, sending their supplies to Teva instead. So that's another lawsuit. The last conference call was a mess, with the company unhappy with their lack of supplies and unable to predict their near term revenues. Go ahead and write in a bad quarter, I don't care. Their p.e. is (bleep) 5. $200 million in profits and they're growing those profits annually at 300%. And those numbers include a bad quarter. Which is just theoretical at this point, anyway. The company is looking to make an acquisition to bolster their near term earnings.I ask you, does it really matter? I wouldn't mind a cheaper price. Look at the business, look at what they are doing. Impax is printing money and they have 63 drugs in the pipeline. I want to put real money in this one.The nicest thing about this company, for those of you who hate the bottom-feeders--and I am with you--is that this company is actually making the transition to real pharmaceutical company. They have two unique drugs in phase III trials, an MS drug and a Parkinson's drug. They are particularly happy with the Parkinson's drug. They file in Q4 of this year. Glaxo has already signed on as a partner for international sales. Impax gets $11 million in cash, plus $125 million if the drug is approved, plus double digit royalties. The stock has done nothing but go up in two years. It's beating Apple, man. And the scary thing is that the near term uncertainty is actually suppressing the stock. Speaking of beating Apple:http://finance.yahoo.com/q/bc?t=my&s=TEVA&l=on&z=l&q=l&c=aaplWow. I'm sorry I missed that. But I'm ready for the sequel.
Cheap price/earnings at 4.30. Plenty of room for growth with market cap of 1.18 billion. Very low debt/equity levels makes it extremely attractive. Specialty pharma company in niche industry.
This is an interesting niche in the generic pharmaceutical market. The creation of sustained-release products is vital in many areas to create a valuable generic alternative to innovator products. This technology should create lasting partnerships for IPXL and the potential for growth. As more products requiring sustain-release formulations lose patent protection if positioned properly this company could continue to be very interesting.
more generics coming off patent, this specialty generic maker can handle the difficult ones
good cash position, insider purchases
I have been trading IPXL for years. Was stuck holding thousands of shares when delisted. Lucky enough to double up in the stock when it was re-listed at about $5.00 a share. This stock will easily trade back to it's old high trading range, about $25 - 30. in the next year or so.
Lowest P/E and growing product & sales lines
As of 1Q10, IPXL has zero debt, over 130M cash in hand, 52 products in pipeline, 42 marketed ANDAs with another 32 pending at the FDA. Two NDAs for Parkinson's ongoing. Plus 4Q sales appear to ramp up each year.
Undervalued small cap growth story
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions